Brought to you by 
Helsinn gets rights to Advancell's chemo injury drug candidate
17 Jun 2014
Executive Summary
Advancell SL (oncology, CNS, and dermatology therapeutics) has granted Swiss drug and device company Helsinn Group exclusive worldwide rights to develop, manufacture, and sell ATH008, a topical cream in Phase IIb trials for the prevention and treatment of palmoplantar erythrodysesthesia syndrome (PPES) and hand-foot skin reactions (HFSR).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Topical Delivery
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Helsinn gets rights to Advancell's chemo injury drug candidate
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice